Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology,Nephrology
Link
https://link.springer.com/content/pdf/10.1007/s11255-022-03437-5.pdf
Reference20 articles.
1. Kumagai T, Ota T, Tamura Y, Chang WX, Shibata S, Uchida S (2017) Time to target uric acid to retard CKD progression. Clin Exp Nephrol 21(2):182–192. https://doi.org/10.1007/s10157-016-1288-2. (Epub 2016 Jun 23)
2. Chang WX, Xu N, Kumagai T, Iijima R, Waki K, Yamanaka M, Nagura M, Arai S, Tamura Y, Shibata S, Fujigaki Y, Uchida S (2017) Uric acid in the follow-up determines 30% decline in estimated GFR over 2 years: a propensity score analysis. Kidney Blood Press Res 42(6):1053–1067. https://doi.org/10.1159/000485593. (Epub 2017 Dec 4)
3. Moriyama T, Itabashi M, Takei T, Kataoka H, Sato M, Shimizu A, Iwabuchi Y, Nishida M, Uchida K, Nitta K (2015) High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a. J Nephrol 28(4):451–456. https://doi.org/10.1007/s40620-014-0154-0. (Epub 2014 Oct 30)
4. Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, de Zoysa JR, Douglas B, Faull R, Harris DC, Hawley CM, Jones GRD, Kanellis J, Palmer SC, Perkovic V, Rangan GK, Reidlinger D, Robison L, Walker RJ, Walters G, Johnson DW, CKD-FIX Study Investigators (2020) Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382(26):2504–2513. https://doi.org/10.1056/NEJMoa1915833
5. Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, Crandall JP, de Boer IH, Elliott TG, Galecki AT, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Lingvay I, Maahs DM, McGill JB, Molitch ME, Perkins BA, Pop-Busui R, Pragnell M, Rosas SE, Rossing P, Senior P, Sigal RJ, Spino C, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M, Doria A, PERL Study Group (2019) Preventing early renal loss in diabetes (PERL) study: a randomized double-blinded trial of allopurinol-rationale, design, and baseline data. Diabetes Care 42(8):1454–1463. https://doi.org/10.2337/dc19-0342. (Epub 2019 Jun 11)
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials;Annals of Medicine;2024-05-13
2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease;Kidney International;2024-04
3. Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis;Frontiers in Pharmacology;2024-03-26
4. Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis;BMC Nephrology;2024-02-23
5. The Effect of Hyperuricemia and Allopurinol Treatment Outcome of Greft in Kidney Transplant Recipients;Cukurova Anestezi ve Cerrahi Bilimler Dergisi;2023-12-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3